Following extensive clinical field trials DSA is now proud to introduce world’s fastest COVID-19 detection product. Just one exhalation, and our screening algorithm makes a distinction between positive or negative result. The system is ready for a new person every 2-3 minutes. 

Press Release, January 14th, 2022

World’s fastest COVID-19 detection is here 

Finnish medical device company Deep Sensing Algorithms Ltd (DSA) has completed the development of the world’s first ultra-rapid COVID-19 detection technology. The DSA BreathPass™ solution, which provides a result in less than a minute, now carries the EU wide medical CE certification and is available for deliveries.  

DSA BreathPass™ is a portable, handheld device that analyses exhaled breath to detect COVID-19 infection. The human defense mechanisms start immediately after the infection and the metabolic byproducts of the person’s immune response start to appear in exhaled breath within the same day. 

The product is simple to use – an individual simply breathes once into the device, and an algorithm provides a result after the measuring period of 45 seconds. The device can be ready for the next individual in 2 minutes. 

The solution is intended for detecting COVID-19 infection in both asymptomatic and pre-symptomatic people. Due to the early warning nature of the COVID-19 detection, it is suited for screening applications where healthy feeling and asymptomatic people wish to receive assurance of their condition. 

“Our novel DSA BreathPass™ solution can make a real difference in the fight against COVID-19. It is low-cost, non-invasive, and highly scalable”, says Pekka Rissanen, CEO of DSA. “We are driven to provide a disruptive COVID screening solution that helps individuals, families, and communities return to normal at work, school, and play.”

For more information:            

Pekka Rissanen

Chief Executive Officer

Deep Sensing Algorithms Ltd

+358 400 648 568

How does it work?


The unit contains a set of carefully selected and configured nanosensors that record Volatile Organic Compounds (VOC) and other substances connected to the biomarkers to be identified in exhaled breath gas. The biomarker VOC’s are born in human metabolism and their known relation – the VOC profile – with a given disease forms the basis for the analysis.

DSA BreathPass™ communicates with an Artificial Intelligence based cloud algorithm to calculate how well the measured breathprint of the individual’s VOC profile matches with the known COVID-19 features. The results are available immediately.

DSA BreathPass™ and future development versions will be brought available for early detection of diseases such as lung and colon cancers and chronic obstructive pulmonary disease (COPD).

View Data Sheets

Deep Sensing Algorithms Ltd Oy

Tuurnankatu 5
FI-33270 Tampere

Business ID: 3139958-7

Visiting address:
Hämeenkatu 14 C 25
FI-33100 Tampere

See map »


Copyright © 2022 Deep Sensing Algorithms Ltd Oy